US › Healthcare

EyePoint, Inc (EYPT)

US · Healthcare · Biotechnology

$11.67-6.04%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$696,000
Revenue YoY
-97.2%
Net profit
$-84.8M
Profit YoY
-87.7%
EPS
$-0.99
EPS estimate
$-0.81
Net margin
-12,188.5%

EPS came in at -0.99 against a street estimate of -0.81 — a miss of 22.2%.

Key statistics

Market cap
$1.03B
Forward P/E
6.2
P/B
4.46
Book value
$0.40
EPS (TTM)
$-3.51
52-week high
$19.11
52-week low
$9.40
50-day MA
$13.14
200-day MA
$14.09
Beta
1.74

Analyst view

Analysts rate EyePoint, Inc a strong buy (13 buy, 0 hold, 0 sell out of 13) with an average price target of $40.50.

Shareholding

Insiders
3.68%
Institutions
112.24%

Largest institutional holders

FundStake
Suvretta Capital Management, LLC9.90%
Cormorant Asset Management, LLC9.86%
BlackRock Inc8.57%
Federated Hermes Inc6.77%
Franklin Resources Inc6.02%
HHG PLC4.30%
Vanguard Capital Management, LLC4.25%
Adage Capital Partners Gp LLC3.94%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for EyePoint, Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.